Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

OBJECTIVE: We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). DESIGN: Phase II and III, multicenter, open-label, randomized controlled trials. METHODS: 108 and 343 children with treat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Endocrinol
Autori principali: Luo, Xiaoping, Hou, Ling, Liang, Li, Dong, Guanping, Shen, Shuixian, Zhao, Zhuhui, Gong, Chun Xiu, Li, Yuchuan, Du, Min-lian, Su, Zhe, Du, Hongwei, Yan, Chaoying
Natura: Artigo
Lingua:Inglês
Pubblicazione: Bioscientifica Ltd 2017
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488390/
https://ncbi.nlm.nih.gov/pubmed/28566441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-16-0905
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi